serum eGFR

Overview

Serum eGFR is the estimated glomerular filtration rate calculated from a serum filtration marker — creatinine, cystatin C, or both — together with age and sex, and it is among the most widely used indicators of kidney function in practice. The qualifier "serum" distinguishes it from a measured GFR obtained by clearing an exogenous marker such as inulin or iohexol, and from creatinine clearance collected over timed urine: the serum-based estimate needs a single blood draw, which is why it is reported automatically with routine chemistry and why nearly all clinical decisions rest on it. The abbreviation is easily confused with EGFR, the epidermal growth factor receptor (EGFR), an unrelated cell-surface receptor protein and oncology drug target.

Its value depends on how well the marker reflects filtration. Creatinine is generated in proportion to muscle mass, so the estimate reads falsely high in sarcopenic or malnourished patients and falsely low in the very muscular, and is disturbed by drugs such as trimethoprim and cimetidine that block tubular creatinine secretion without changing filtration. Cystatin C avoids the muscle dependence and is used to confirm a discrepant creatinine result, with the combined equation the most accurate of the three. Current equations omit the race coefficient once used in the United States, after it was judged to systematically overestimate function in Black patients and delay their access to specialist care and transplant listing.

Clinically, serum eGFR stages chronic kidney disease, tracks progression, determines drug eligibility and dosing for renally cleared agents, and serves as a trial endpoint where the slope of decline rather than any single value defines benefit. It is interpreted alongside the urine albumin-creatinine ratio (UACR), which detects glomerular damage while filtration is still preserved, and in research alongside markers such as plasma sTIM-3. It appears both as an outcome and as the target of interventions intended to slow renal decline, including therapies in IgA nephropathy and studies of kidney function trajectories after acute kidney injury — a setting where the estimate is unreliable while function is changing, since it assumes a steady state that acute injury violates.

Recent Publications Summary

Recent publications involving serum eGFR focused primarily on its use as a kidney function metric rather than as a direct therapeutic target. One machine-learning study used longitudinal glomerular filtration rate (eGFR) trajectories after acute kidney injury hospitalization to predict membership in a high-risk trajectory class associated with subsequent kidney replacement therapy initiation, highlighting serum eGFR as a prognostic marker for post-AKI renal decline 42203305May. Another large-scale European genetic study examined the shared genetic architecture of eGFR and albuminuria, with a particular focus on type 2 diabetes, to better define common and population-specific determinants of chronic kidney disease risk 42191235May.

Across these studies, serum eGFR was used in combination with other clinical or molecular features to stratify kidney disease risk and understand disease biology. The AKI trajectory model emphasized serial eGFR monitoring as an input for predicting adverse renal outcomes, while the genetic study paired eGFR with urine albumin-creatinine ratio (UACR) to investigate overlapping kidney-function and albuminuria loci 42203305May42191235May. Together, these publications reinforce serum eGFR as a central clinical metric for assessing renal function, tracking progression, and supporting risk prediction in chronic kidney disease and post-AKI follow-up 42203305May42191235May.

What Changes, What Holds

1. Serum eGFR is being used as a prognostic trajectory marker rather than only a static kidney-function readout
NEW DIRECTION Longitudinal eGFR patterns after acute kidney injury add a risk-stratification role that goes beyond the Overview’s emphasis on staging CKD and monitoring renal function over time. The new work suggests that serial serum eGFR can identify a subgroup with higher downstream kidney-replacement risk, but it does not replace the established use of eGFR as a general filtration metric. The genetic study also extends the baseline by linking eGFR with albuminuria biology in type 2 diabetes 42203305May42191235May.

2. Serial eGFR monitoring and paired biomarker analysis now look more central to risk modeling and disease biology
REINFORCES These studies strengthen the existing view that serum eGFR is most useful when interpreted alongside other markers such as UACR and in longitudinal follow-up. Rather than changing what eGFR is, they sharpen how it is applied: as an input for prediction, a companion to albuminuria, and a tool for dissecting shared kidney-disease determinants. The baseline already allowed this kind of combined use, so the new work mainly confirms and extends that practice 42203305May42191235May.

Overview update candidates: serial eGFR trajectories for post-AKI risk prediction; shared genetic architecture of eGFR and albuminuria; especially in type 2 diabetes.